Anders Månsson, RhoVac CEO
Swedish biotech crumbles in face of PhII failure of prostate cancer vaccine
Swedish biotech RhoVac saw its shares plummet by 90% Monday after its lead cancer vaccine candidate failed a Phase II study.
In approximately 180 patients …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
